Referências Bibliográficas
OLIVEIRA AL - 2007
58
Khedhaier A, Remadi S, Corbex M, Ahmed SB, Bouaouina N, Mestiri S, et al. Glutathione S-
Transferases (GSTT1 and GSTM1) gene deletions in tunisians: susceptibility and prognostic
implications in breast carcinoma. Br J Cancer. 2003; 89:1502-7.
Konishi I, Nambu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y, et al. Tumor response to
neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not
GST-π in the tumor cells of cervical carcinoma Gynecol Oncol. 1998; 70:365-71.
Kroger N, Acterrath S, Hegewisch-Becker K, Mross K, Zander AR. Current options in
treatment of anthracycline-resistant breast cancer. Cancer Treat Rev. 1999; 25:279-91.
Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for preparation of HMW DNA
from blood for RFLP studies. Nucleic Acids Res1991;19:5444.
L’Ecuyer T, Allebban Z, Thomas R, Vander Heide RV. Glutathione S-transferase over
expression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ
Phisiol. 2004; 286:H2057-64.
Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer.
Endocr Relat Cancer. 2003; 10:43-73.
Leyland-Jones BR, Towsend AJ, Tu CD, Cowan KH, Goldsmith ME. Antineoplastic drug
sensitivity of human MCF-7 breast cancer cells stably transfected with a human α class
glutathione S-transferase gene. Cancer Res. 1991; 51:587-94.
Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P.
Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics
and survival in advanced breast cancer. Breast Cancer Res. 1999;1:81-7.
Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA.
Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction
between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis. 2001;
22:1053-60.
MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, et al. Primary
chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical
detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996;
74:1458-65.
Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, et al. Survival
advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year
analysis--an intergroup study. J Clin Oncol. 1998;16:3486-92.
McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer
incidence and therapy. Oncogene. 2006; 25:1639-48.
Millikan R, Pittman G, Tse CK, Savitz DA, Newman B, Bell D. Glutathione S-transferases
M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9:567-73.
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma V, Benhamou S, et al. Glutatione
S-transferase M1, M3, P1 and T1 genetic polymorphisms and susceptibility to breast cancer.
Cancer Epidemiol Biomarkers Prev. 2001; 10:229-36.